Carcinoma, Hepatocellular
"Carcinoma, Hepatocellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Descriptor ID |
D006528
|
| MeSH Number(s) |
C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160
|
| Concept/Terms |
Carcinoma, Hepatocellular- Carcinoma, Hepatocellular
- Carcinomas, Hepatocellular
- Hepatocellular Carcinomas
- Liver Cell Carcinoma, Adult
- Liver Cancer, Adult
- Adult Liver Cancer
- Adult Liver Cancers
- Cancer, Adult Liver
- Cancers, Adult Liver
- Liver Cancers, Adult
- Liver Cell Carcinoma
- Carcinoma, Liver Cell
- Carcinomas, Liver Cell
- Cell Carcinoma, Liver
- Cell Carcinomas, Liver
- Liver Cell Carcinomas
- Hepatocellular Carcinoma
- Hepatoma
- Hepatomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Hepatocellular".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Hepatocellular".
This graph shows the total number of publications written about "Carcinoma, Hepatocellular" by people in this website by year, and whether "Carcinoma, Hepatocellular" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 4 | 5 |
| 1996 | 2 | 1 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 3 | 4 |
| 2001 | 6 | 1 | 7 |
| 2002 | 7 | 4 | 11 |
| 2003 | 4 | 3 | 7 |
| 2004 | 6 | 3 | 9 |
| 2005 | 7 | 1 | 8 |
| 2006 | 4 | 2 | 6 |
| 2007 | 9 | 1 | 10 |
| 2008 | 10 | 5 | 15 |
| 2009 | 13 | 4 | 17 |
| 2010 | 16 | 3 | 19 |
| 2011 | 14 | 3 | 17 |
| 2012 | 11 | 1 | 12 |
| 2013 | 19 | 0 | 19 |
| 2014 | 14 | 2 | 16 |
| 2015 | 21 | 2 | 23 |
| 2016 | 16 | 3 | 19 |
| 2017 | 22 | 3 | 25 |
| 2018 | 26 | 1 | 27 |
| 2019 | 40 | 1 | 41 |
| 2020 | 47 | 0 | 47 |
| 2021 | 38 | 2 | 40 |
| 2022 | 53 | 0 | 53 |
| 2023 | 37 | 1 | 38 |
| 2024 | 34 | 6 | 40 |
| 2025 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Hepatocellular" by people in Profiles.
-
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis. Hepatol Commun. 2025 Jul 01; 9(7).
-
Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study. Am J Gastroenterol. 2025 Apr 23; 120(8):1800-1808.
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
-
Benefits and harms of hepatocellular carcinoma screening outreach in patients with cirrhosis: a multicenter randomized clinical trial. J Natl Cancer Inst. 2025 Feb 01; 117(2):262-269.
-
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Feb 01; 11(2):136-144.
-
Risk of carcinomas among children and adolescents with birth defects. Cancer Epidemiol. 2025 Apr; 95:102748.
-
"Update on pediatric primary liver tumors". Virchows Arch. 2025 Jan; 486(1):23-47.
-
ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis. Cancer Res. 2025 Jan 15; 85(2):299-313.
-
Magnetic resonance imaging of hepatocellular carcinoma: a spectrum of uncommon morphologic subtypes, unusual imaging patterns and mimics. Abdom Radiol (NY). 2025 07; 50(7):3020-3035.
-
Common pitfalls and diagnostic challenges in the application of LI-RADS CT/MRI algorithms: a comprehensive review. Abdom Radiol (NY). 2025 07; 50(7):2944-2957.